Varicella zoster virus the ACIP recommended a second dose of vaccine before school entry to ensure the maintenance of high levels of varicella immunity. In 2006, the United States Food and Drug Administration approved Zostavax for the prevention of shingles. Zostavax is a more concentrated formulation of the Varivax vaccine, designed to elicit an immune response in older adults whose immunity to VZV wanes with advancing age. A systematic review by the Cochrane Library shows that Zostavax reduces the incidence of shingles by almost 50%. Shingrix is a "V. zoster" vaccine developed by GlaxoSmithKline which was approved in the United States by the
European Centre for Disease Prevention and Control The office of the Chief Scientist oversees the seven Disease Programmes, the Microbiology Coordination Section and the Scientific Advice Coordination Section. The Disease Programmes focus on specific disease groups: Two shared-resource units – Surveillance and Response Support, and Public Health Capacity and Communication – provide specialist expertise. The Information and Communication Technologies Unit provides infrastructure, application development and support. The Resource Management and Coordination Unit controls ECDC’s human and financial resources. ECDC publishes numerous scientific and technical reports covering various issues related to the prevention and control of communicable diseases. Comprehensive reports from key technical and scientific meetings are also